A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516199-14-00

Acronym

GS-US-418-3899

Enrollment

Registered

2024-09-03

Start date

2017-04-12

Completion date

Unknown

Last updated

2025-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis (UC)

Brief summary

Safety, evaluated through AEs, clinical laboratory tests, and vital signs

Detailed description

To evaluate the effect of filgotinib on partial Mayo Clinic Score (MCS)

Interventions

DRUGJyseleca 100 mg film-coated tablets

DRUGJyseleca 200 mg film-coated tablets

DRUGComposition apart from the active substance otherwise to identical to IMP

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Safety, evaluated through AEs, clinical laboratory tests, and vital signs	—

Secondary

Measure	Time frame
To evaluate the effect of filgotinib on partial Mayo Clinic Score (MCS)	—

Countries

Hungary

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026